Skip to main content
. 2021 Feb 23;39(12):1317–1328. doi: 10.1200/JCO.20.01366

FIG 4.

FIG 4.

Subgroup analyses of progression-free survival by Independent Radiology Adjudication Committee in the intent-to-treat population treated with R2-CHOP versus placebo/R-CHOP. aPrespecified stratification factor. CrCl, creatinine clearance; DLBCL, diffuse large B-cell lymphoma; HR, hazard ratio; IPI, International Prognostic Index; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP, lenalidomide plus R-CHOP.